Hypera’s Buscopan Deal Approved by Brazil Antitrust Body

Brazil antitrust regulator, known as Cade, unanimously approved in a session broadcast on-line the purchase by Hypera of Buscopan drug line from Boehringer Ingelheim GmbH for 1.3b reais.

• Deal was approved on condition that Hypera divests from the products that compete with Buscopan
• Hypera, since the beginning of the operation, presented a proposal to sell its medicine Neocopan Composto to the company Uniao Quimica Farmaceutica Nacional to guarantee the approval of the deal
  • Sale of Neocopan Composto has been carried out and approved by Cade previously

Original Story:
Cade aprova compra do Buscopan pela Hypera com venda de ativo

To ...